In this study, we investigated the association of FLT3-ITD gene mutation with bone marrow blast count, CD34, Cyclin D1 (a cell proliferation marker), Bcl-xL (an anti-apoptotic agent) and hENT1 (a cytarabine transporter) expressions that lead to poor prognosis and determine treatment outcomes in AML patients with this mutation. This evidence concerns the gene CD34 and acute myeloid leukemia.